SEC Form 4 · accession 0001179110-18-010987
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Beth Taylor
Officer — VP Finance & Chief Acctg Offcr
Period of report
Aug 28, 2018
Accepted (ET)
Aug 29, 2018 · 2:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 28, 2018 | S | 7,892 | $20.00 | D | 63,363 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 7,892 shares in a single transaction, at a price per share of $20.0000. The shares were sold by Merrill Lynch pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.